Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects and Safety of GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma a Prospective, Single-arm, Single-center Phase II Study

Next Previous
Trial Profile

Effects and Safety of GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma a Prospective, Single-arm, Single-center Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donafenib (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use

Most Recent Events

  • 16 Aug 2024 Planned number of patients changed from 35 to 93.
  • 16 Aug 2024 Planned End Date changed from 31 Mar 2025 to 31 Mar 2027.
  • 16 Aug 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top